Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classifica tra le azioni #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prezzo delle azioni
$193.62
Capitalizzazione di mercato
$150.08B
Variazione (1 giorno)
2.76%
Variazione (1 anno)
184.69%
Paese
GB
Scambia AstraZeneca PLC (AZN)

Categoria

Storico del prezzo dell'azione per AstraZeneca PLC (AZN)
Prezzo di chiusura più alto: $191.96 il 2026-03-01

Prezzo di chiusura più basso: $4.88 il 1993-05-01
Storico del prezzo dell'azione di AstraZeneca PLC dal 1993 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 8.71%
2025 36.83%
2024 1.90%
2023 -4.59%
2022 21.85%
2021 9.28%
2020 5.13%
2019 27.66%
2018 15.57%
2017 23.32%
2016 -20.21%
2015 -6.16%
2014 24.29%
2013 21.08%
2012 4.55%
2011 -3.37%
2010 2.75%
2009 17.01%
2008 -13.01%
2007 -18.66%
2006 15.35%
2005 24.93%
2004 -17.36%
2003 28.70%
2002 -19.27%
2001 -10.34%
2000 18.78%
1999 -3.47%
1998 28.64%
1997 25.37%
1996 38.87%
1995 45.94%
1994 12.44%
1993 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$885.05 17.33%
US
$241.79 56.64%
US
$212.48 18.64%
US
$150.20 37.22%
CH
$117.65 48.60%
US